Literature DB >> 8132349

Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats.

A W Cripps1, M L Dunkley, R L Clancy.   

Abstract

The aim of this study was to determine the efficacies of prior mucosal (oral, intra-Peyer's patch, or intratracheal) and systemic (subcutaneous) immunizations with killed Pseudomonas aeruginosa in clearance of an acute P. aeruginosa respiratory infection in rats. Rats were immunized with paraformaldehyde-killed P. aeruginosa at various doses, and 2 weeks later, the rats were challenged with a log10 dose of 8.7 live bacteria. This dose was fatal for unimmunized rats, with death occurring approximately 12 h after challenge. The numbers of surviving bacteria in the airways and lung tissue were determined by analyses of bronchoalveolar lavage fluid (BAL) and lung homogenate samples, respectively. Enhanced bacterial clearance was associated with survival of intra-Peyer's patch-immunized rats. Determination of bacterial clearance in BAL 4 h after challenge demonstrated that the use of all immunization routes led to significant clearance compared with the bacterial levels in unimmunized controls (the order of effectiveness was intra-Peyer's patch > oral-intratracheal > intratracheal > subcutaneous > oral). Bacterial clearance in the lung homogenate was also significantly greater for all immunization routes than in the unimmunized controls (the order of effectiveness was intra-Peyer's patch > subcutaneous > oral-intratracheal > oral = intratracheal). Prior oral immunization with killed P. aeruginosa also induced enhanced bacterial clearance of heterologous strains of P. aeruginosa, Haemophilus influenzae, and to a lesser extent, Klebsiella pneumoniae. Because of the ease of antigen delivery, oral immunization with killed P. aeruginosa may be an important route of immunization for induction of enhanced bacterial clearance of subsequent acute respiratory infection with P. aeruginosa and other gram-negative bacteria.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8132349      PMCID: PMC186298          DOI: 10.1128/iai.62.4.1427-1436.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

1.  Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis.

Authors:  M M Brett; A T Ghoneim; J M Littlewood
Journal:  Arch Dis Child       Date:  1986-11       Impact factor: 3.791

2.  An animal model demonstration of enhanced clearance of nontypable Haemophilus influenzae from the respiratory tract after antigen stimulation of gut-associated lymphoid tissue.

Authors:  F J Wallace; R L Clancy; A W Cripps
Journal:  Am Rev Respir Dis       Date:  1989-08

3.  Distribution and functional characteristics of antigen-specific helper T cells arising after Peyer's patch immunization.

Authors:  M L Dunkley; A J Husband
Journal:  Immunology       Date:  1987-08       Impact factor: 7.397

4.  Effect of oral immunization with Pseudomonas aeruginosa on the development of specific antibacterial immunity in the lungs.

Authors:  J Freihorst; J M Merrick; P L Ogra
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

Review 5.  Mucosal immune interactions in intestine, respiratory tract and mammary gland.

Authors:  A J Husband
Journal:  Prog Vet Microbiol Immunol       Date:  1985

6.  Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.

Authors:  S J Cryz; J C Sadoff; D Ohman; E Fürer
Journal:  J Lab Clin Med       Date:  1988-06

7.  Effector mechanisms of intestinally induced immunity to Pseudomonas aeruginosa in the rat lung: role of neutrophils and leukotriene B4.

Authors:  A Buret; M Dunkley; R L Clancy; A W Cripps
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

8.  In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide.

Authors:  G B Pier; D Thomas; G Small; A Siadak; H Zweerink
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

9.  Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model.

Authors:  H E Gilleland; L B Gilleland; J M Matthews-Greer
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

10.  Immune enhancement of pulmonary clearance of nontypable Haemophilus influenzae.

Authors:  E J Hansen; D A Hart; J L McGehee; G B Toews
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

View more
  27 in total

1.  Identification and characterization of a chitinase antigen from Pseudomonas aeruginosa strain 385.

Authors:  S E Thompson; M Smith; M C Wilkinson; K Peek
Journal:  Appl Environ Microbiol       Date:  2001-09       Impact factor: 4.792

2.  Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit.

Authors:  A Rudin; G C Riise; J Holmgren
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

3.  Bombesin recovers gut-associated lymphoid tissue and preserves immunity to bacterial pneumonia in mice receiving total parenteral nutrition.

Authors:  R C DeWitt; Y Wu; K B Renegar; B K King; J Li; K A Kudsk
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

4.  Immunologic correlates of protection against rotavirus challenge after intramuscular immunization of mice.

Authors:  S E Coffin; C A Moser; S Cohen; H F Clark; P A Offit
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

5.  Development of a recombinant epsilon toxoid vaccine against enterotoxemia and its use as a combination vaccine with live attenuated sheep pox virus against enterotoxemia and sheep pox.

Authors:  Dev Chandran; Sureddi Satyam Naidu; Parthasarathy Sugumar; Gudavalli Sudha Rani; Shahana Pallichera Vijayan; Deepika Mathur; Lalit C Garg; Villuppanoor Alwar Srinivasan
Journal:  Clin Vaccine Immunol       Date:  2010-04-28

6.  Effector mechanisms of protection against Pseudomonas aeruginosa keratitis in immunized rats.

Authors:  A Thakur; J Kyd; M Xue; M D Willcox; A Cripps
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

7.  Pulmonary immunity to Pseudomonas aeruginosa in intestinally immunized rats roles of alveolar macrophages, tumor necrosis factor alpha, and interleukin-1 alpha.

Authors:  A Buret; M L Dunkley; G Pang; R L Clancy; A W Cripps
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

8.  Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection.

Authors:  Ryka Moore; Jennelle M Kyd; Rosemary Carzino; Davide Armstrong; Keith Grimwood; Diana C Otczyk; Allan W Cripps
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

9.  Intranasal immunization with a colloid-formulated bacterial extract induces an acute inflammatory response in the lungs and elicits specific immune responses.

Authors:  A Rial; D Lens; L Betancor; H Benkiel; J S Silva; J A Chabalgoity
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

Review 10.  Mouse models for human otitis media.

Authors:  Dennis R Trune; Qing Yin Zheng
Journal:  Brain Res       Date:  2009-03-06       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.